EG 427
Genetic medicines developer for prevalent chronic diseases in neurology.
2
Funding Rounds
$19.6m
Money raised
Overview
Genetic medicines developer for prevalent chronic diseases in neurology.
- Website:
- Headquarters: Paris
- Social accounts: linkedin
Funding
Funding series
Funding Series Analysis
The company EG 427 has raised a total of $19.6m in funding over 2 rounds.
Key Insights:
- EG 427 July 2023 Series A Funding Round: $5.6m
- EG 427 March 2021 Series A Funding Round: $14m
EG 427 July 2023 Series A Funding Round
$5.6m
EG 427 March 2021 Series A Funding Round
$14m
Industries
EG 427 is active in the following industries: